KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Change in Working Capital (2016 - 2025)

Historic Change in Working Capital for Gsk (GSK) over the last 15 years, with Q3 2023 value amounting to -$1.8 billion.

  • Gsk's Change in Working Capital fell 22816.43% to -$1.8 billion in Q3 2023 from the same period last year, while for Sep 2023 it was -$3.7 billion, marking a year-over-year decrease of 4362.04%. This contributed to the annual value of -$82.8 million for FY2018, which is 3233.93% up from last year.
  • Gsk's Change in Working Capital amounted to -$1.8 billion in Q3 2023, which was down 22816.43% from -$232.2 million recorded in Q4 2022.
  • Gsk's Change in Working Capital's 5-year high stood at $1.3 billion during Q2 2022, with a 5-year trough of -$1.8 billion in Q3 2023.
  • Over the past 5 years, Gsk's median Change in Working Capital value was -$685.9 million (recorded in 2020), while the average stood at -$611.2 million.
  • In the last 5 years, Gsk's Change in Working Capital soared by 51494.1% in 2020 and then tumbled by 22816.43% in 2023.
  • Gsk's Change in Working Capital (Quarter) stood at -$1.3 billion in 2019, then soared by 50.62% to -$628.5 million in 2020, then tumbled by 73.51% to -$1.1 billion in 2021, then soared by 78.7% to -$232.2 million in 2022, then crashed by 681.04% to -$1.8 billion in 2023.
  • Its last three reported values are -$1.8 billion in Q3 2023, -$232.2 million for Q4 2022, and -$552.7 million during Q3 2022.